skip to Main Content

April 6, 2021
Community Update on Current and Future COVID-19 Vaccine Trials
On Tuesday, April 6th Treatment Action Group (TAG) hosted a webinar for community advocates with a status update on current and future COVID-19 vaccine trials and answers to questions related to safety and efficacy data.

April 4, 2021
TAG Comments on NIST’s Proposed Rulemaking Changes
Letter / Comment
TAG submitted comments in response to the National Institute of Standards and Technology’s (NIST) proposed change to rulemaking, strongly opposing amendments to remove crucial public health safeguards from the Bayh-Dole Act. March-in rights and other provisions to hold manufacturers accountable when federally funded inventions are exorbitantly priced and are critically…

April 1, 2021
Civil Society Letter to Donors, Countries, and Health Actors to Improve Access to GeneXpert and Other Diagnostics
Letter / Comment
TAG led an open letter appealing to donors, countries, and health actors to improve access to GeneXpert and other diagnostics for COVID-19, TB, HIV, HBV, HCV, and other diseases by applying collective leverage in negotiations with Cepheid for lower prices and sufficient volumes; establishing cost-of-goods-sold (COGS)-plus and volume-based pricing for…

March 18, 2021
Research Toward a Cure Trials
A listing of clinical trials and observational studies related to the research effort to cure HIV infection, mainly derived from the clinicaltrials.gov online registry. Click the trial registry identifier numbers for a link to the full entry containing detailed information on the trial design, enrollment criteria, principal investigators and location(s).

March 16, 2021
Letter to President Biden Urging Nomination of U.S. Global AIDS Coordinator
Letter / Comment
TAG is one of the organizations that signed onto this letter urging President Biden to quickly nominate a U.S. global AIDS coordinator along with a U.S. special representative for global health diplomacy. They’re also requesting that the President’s Emergency Plan for AIDS Relief (PEPFAR), remain within the State Department.

March 5, 2021
How Lessons Learned from the HIV Epidemic Can Inform Efforts to Address the COVID-19 Pandemic Through a Racial Equity Lens
Webinar / Presentation
Join us on March 15, 2021 at 4:00 p.m. EST for this free webinar, which will discuss a variety of issues concerning disenfranchised communities being disproportionately affected by COVID-19.

February 25, 2021
Civil Society Letter to Cepheid Requesting Lower Prices for Xpert SARS-CoV-2 Tests and Increased Volumes Distributed to LMICs
Letter / Comment
TAG signed onto this letter requesting that diagnostics company Cepheid increase access to Xpert SARS-CoV-2 tests in low- and middle-income countries (LMICs) by committing a greater proportion of its SARS-CoV-2 test manufacturing capacity to LMICs and by lowering cost of its tests for SARS-CoV-2, TB, HIV, HCV, and other diseases…

February 17, 2021
Pre- and Post-CROI Community HIV Cure Research Workshop
Webinar / Presentation
The 2021 Community HIV Cure Research Workshop will take place virtually this year due to the ongoing COVID-19 pandemic. The workshop sessions will be held on Thursday, March 4 and Friday, March 5, 2021 (right before CROI 2021), and then on Tuesday, March 16, 2021 (after the conference).

January 26, 2021
TAG/COVID-19 Prevention Network: HIV, COVID-19 Outcomes and Implications for COVID-19 Vaccines
Webinar / Presentation
Join TAG and COVID-19 Prevention Network (CoVPN) On Tuesday February 2nd at 4pm ET / 1pm PT, at a webinar for community advocates on COVID-19 outcomes in people living with HIV and implications for COVID-19 vaccines.

January 21, 2021
Good COPs or Bad COPs: Promoting Interventions for Co-Infections and Advanced HIV Disease in 2021 PEPFAR Country Operational Plans (COPs)
Webinar / Presentation
On January 21, 2021, Treatment Action Group (TAG), Health GAP, and MSF Access Campaign presented this webinar on how to engage in PEPFAR COPs advocacy and promote the prioritization of interventions that address co-infections and advanced HIV disease.

Back To Top